Caribou Biosciences Presents Encouraging Clinical Data from
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell...
Source: globenewswire.com
Updated Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Updated Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Updated Phase Today - Breaking & Trending Today
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to...
Source: marketscreener.com
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) - G1 Therapeutics (NASDAQ:GTHX)
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data
Source: benzinga.com
G1 Therapeutics Announces Upcoming Presentation at the 2024
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting...
Source: globenewswire.com
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting
G1 Therapeutics, Inc. announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate sacituzumab govitecan on...
Source: marketscreener.com